C-YYVQMultiomic
multi-omics, AI, precision medicine
discoverydiscovering
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-YYVQ
C-YYVQC-YYVQmulti-omics, AI, precision medicine
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Press Release Skip to content Products Solutions Learn Company Support Recommended Links Products Instruments Kits & Reagents Selection Tools Software & Analysis Services Popular Products Explore All Products Instruments Sequencing Platforms Microarray Scanners IVD Instruments Financing Options All Instruments NovaSeq X innovation roadmap Future-ready: Built to accelerate performance and value See timeline Kits & Reagents Library Preparation Kits Sequencing Reagents Microarray Kits Clinical Research Products IVD Products All Kits & Reagents Illumina 5-base solution Detect five … Large-Scale Bull Genome Sequencing Featured News 2020 Agricultural Greater Good Grant Winner 2019 Agricultural Greater Good Grant Winner Earth BioGenome Project More News Illumina StrataMap Spatial Scalable, unbiased, barrier-free Learn more Methods & Education Complex Disease Genomics Disease Association Studies Gene Target Identification & Pathway Analysis Polygenic Risk Scores Methods Illumina Training Illumina StrataMap Spatial Scalable, unbiased, barrier-free Lea … global adoption of NGS in cancer care. As part of this agreement, Illumina will grant Roche rights to develop and distribute in-vitro diagnostic (IVD) tests on Illumina’s NextSeq™ 550Dx System , as well as on its future portfolio of diagnostic (Dx) sequencing systems, including the forthcoming NovaSeqDx. Roche will in turn collaborate with Illumina to complement Illumina’s comprehensive pan-cancer assay, TruSight Oncology 500 (TSO 500), with new companion diagnostic (CDx) cla … Australian general public. Innovative technologies At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the
How multiomic data and AI are transforming science | Rodrigo Benevides posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agre … ens of billions of dollars by 2030. At Genomac, we help our clients harness and apply bioinformatics and machine learning in their drug discovery workflows, reducing analysis cost by up to 30%. Not only that, we also train teams and build customized workflows for organizations and individuals looking to become experts in AI-powered diagnostics and machine learning model development. If you’re a researcher, biotech innovator, or life scientist passionate about precision medici
CENTOGENE Announces Expansion of Data Access and Collaboration Agreement With Pfizer | CENTOGENE About us Centogene Our Story Leadership Team Careers News Contact Us Insights & Quality Accreditations Medical Reporting Variant Reclassification Innovation CENTOGENE Biodatabank CentoCard ® Diagnostics Products & Solutions Product Overview Multiomic Solutions Whole Genome Sequencing Whole Exome Sequencing Genome Wide CNV Analysis NGS Panels Custom Panels Updated Single Genes Enzymes & Metabolic Biomarker Carrier Screening Updated CentoNIPT CentoDx Clinical areas Cardiovascular Dermat
Hoxton Ventures - Multiomic Health home. approach. team. pipeline. news. contact. careers. Search More info Main menu We back Europe's best tech companies, before the rest of the world believes Hoxton Ventures Hoxton Ventures is an early stage venture capital firm based in London and investing in European technology start-ups that can scale into large, global winners. It focuses on start-ups that either disrupt existing industries or invent entirely new market categories. It was the first institutional investor in Babylon Health, Darktrace and Deliveroo, and its portfolio companies have grown
Ada Ventures - Multiomic Health home. approach. team. pipeline. news. contact. careers. Search More info Main menu Open to Possibility Ada Ventures Ada Ventures is the inclusive venture capital firm rethinking venture capital by finding and funding extraordinary talent where others aren’t looking. It invests at pre-seed and seed across climate, economic empowerment, healthcare and ageing, supporting founders with breakthrough ideas for the hardest problems we face. Since its 2020 launch, the firm’s AUM now exceeds £100m, including investment in fast-growing Bio & Health companies like R.Gr
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
A Multiomic Analysis Reveals How Breast Cancers Disseminated to the Bone Marrow Acquire Aggressive Phenotypes through Tumor-Stroma Tunnels | bioRxiv Skip to main content Home About Submit ALERTS / RSS Search for this keyword Advanced Search New Results A Multiomic Analysis Reveals How Breast Cancers Disseminated to the Bone Marrow Acquire Aggressive Phenotypes through Tumor-Stroma Tunnels View ORCID Profile Saptarshi Sinha , Brennan W. Callow , Alex P. Farfel , Suchismita Roy , Siyi Chen , Shrila Rajendran , Johanna M. Buschhaus , Kathryn E. Luker , Pradipta Ghosh , Gary D. Luker doi: https:// … q 6000 that was purchased with funding from a National Institutes of Health SIG grant (#S10 OD026929). The manuscript also includes data generated through the University of Michigan Advanced Genomics, Flow Cytometry, and Pre-Clinical Imaging shared resources supported in part by the University of Michigan Comprehensive Cancer Center support grant P30CA046592. Footnotes Title and main text updated References Cited 1. ↵ Kennecke H , Yerushalmi R , Woods R , Cheang MC , Voduc D … junction proteins connexins in cancer metastasis, chemoresistance and clinical application . J Biomed Sci . 2019 ; 26 ( 1 ): 8 . OpenUrl CrossRef 14. ↵ Shiozawa Y , Pienta KJ , and Taichman RS . Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors . Clin Cancer Res . 2011 ; 17 ( 17 ): 5553 – 8 . OpenUrl Abstract / FREE Full Text 15. ↵ Buschhaus JM , Rajendran S , Humphries BA , Cutter AC , Muñiz AJ , Ciavattone NG , et al. Effects of iro … rtunities and Challenges in Tunneling Nanotubes Research: How Far from Clinical Application? Int J Mol Sci . 2021 ; 22 ( 5 ). 62. ↵ Sartori-Rupp A , Cordero Cervantes D , Pepe A , Gousset K , Delage E , Corroyer-Dulmont S , et al. Correlative cryo-electron microscopy reveals the structure of TNTs in neuronal cells . Nat Commun . 2019 ; 10 ( 1 ): 342 . OpenUrl CrossRef PubMed 63. ↵ Alarcon-Martinez L , Villafranca-Baughman D , Quintero H , Kacerovsky JB , Dotigny F , Murai KK
Aspira Women’s Health and Cleveland Clinic Expand Strategic Collaboration to Advance AI-Powered Diagnostics in Women’s Health Locations: Abu Dhabi | Canada | Florida | London | Nevada | Ohio | Newsroom News Releases Media Resources News & Views About Contact Us Search May 26, 2026 / News Releases Aspira Women’s Health and Cleveland Clinic Expand Strategic Collaboration to Advance AI-Powered Diagnostics in Women’s Health Collaboration aims to accelerate biomarker discovery, strengthen translational research capabilities, and support scalable clinical validation Media Contact Alicia Reale-Co
AbOliGo Closes Oversubscribed Seed Round AbOliGo AbOliGo Open main menu Home Products Services Resources Conjugation Chemistry & Methods Bioconjugation Optimization Analytical Characterization Single-Cell & Multi-Omics Protein Interaction Assays Multiplex Panel Design Advanced Imaging & Multiplexing Neuroscience Applications Company About Us News Investors Careers Support Open cart Sign In Sign Up Back to News Company News Funding AbOliGo Closes Oversubscribed Round to Accelerate Multiomic Research Tools and Appoints Proven Life Sciences Board 6 August 2025 by Brian Carpenter CAMBR
Ariella Cohain - Chief Technology and Data Officer at Multiomic Health Search Pricing Sign in Sign up EN EN Ariella Cohain Ariella Cohain - Chief Technology and Data Officer at Multiomic Health Morocco Multiomic Health View Ariella Cohain's Email & Phone Number Ariella Cohain Work Chief Technology and Data Officer @ Multiomic Health T Senior Data Scientist @ Thrive Earlier Detection Corp. T Data Scientist @ Thrive Earlier Detection Corp. Ariella Cohain Education 2013 - 2017 PhD in Biomedical Sciences in Genetics & Genomics Icahn School of Medicine at Mount Sinai 2007 - 2011 B.S. in Biomedi
Curiosity. - Multiomic Health home. approach. team. pipeline. news. contact. careers. Search More info Main menu Curiosity. All MOH Jobs Pre-Seed Investors Seed Investors PhD Studentship MultiOmic Health Opportunities MMC Ventures Backing transformative tech Ada Ventures Open to Possibility Verve Ventures Leading Pan-European Venture Capital Investor Hoxton Ventures We back Europe's best tech companies, before the rest of the world believes Selvedge Venture Access Beyond Formic Ventures Fighting Entropy, Putting Humans in Control of Their Own Destiny HOF Capital We help founders build end
Developing precision medicine in Gulf Cooperation Council countries - HIMSS TV Homepage HIMSS TV is your Insider’s Guide to everything HIMSS. We are the world’s first online broadcasting network, focused on global innovation and how information and technology are driving change in healthcare. Home Browse Video Categories Search Videos toggle navigation Home Enter terms to search videos Perform search Latest Videos HIMSS TV @ HIMSS26 HIMSS26 Changemaker Awards HIMSS TV @ HIMSS25 HIMSS25 Changemaker Awards HIMSS TV @ HIMSS24 HIMSS24 Changemaker Awards HIMSS TV @ HIMSS23 HIMSS23 Changemake
Session Multiomic Characterization Of Cancer Development And Progression - 2025sv - PMWC Precision Medicine World Conference Track 4 Track Chair: Kathleen Barnes, Oxford Nanopore Speakers: Nobel Laureate Carol Greider,..."> Track 4 Track Chair: Kathleen Barnes, Oxford Nanopore Speakers: Nobel Laureate Carol Greider,..."> Track 4 Track Chair: Kathleen Barnes, Oxford Nanopore Speakers: Nobel Laureate Carol Greider,..."> Track 4 Track Chair: Kathleen Barnes, Oxford Nanopore Speakers: Nobel Laureate Carol Greider,..." /> Track 4 Track Chair: Kathleen Barnes, Oxford Nanopore Speakers: Nobel Laureat … ogin / My Account Participate REGISTER TO EXHIBIT Prospectus Attendee Breakdown Apply to speak Sponsorship Inquiry media / influencer pass CONTACT US ABOUT Mission Testimonial Past Conferences Past Honorees Past Speakers FAQ GET UPDATES Past Event PMWC, Feb 5-7, 2025 Attend Program Schedule Honorees Speakers Showcases Exhibits + Map Travel Venue Sightseeing Reduced Rates Hotel Flights Login / My Account Participate Register to Exhibit Prospectus Attendee Breakdown Apply to sp … tend Program Speakers Travel Exhibits + Map Main Program View your save program Award Reception Speaker gallery Select part speakers Exhibit gallery Part conferences Participate Register to Exhibit Apply to speak Sponsorship Inquiry ABOUT Login / My Account CONTACT US Get Updates Pittsburgh, pa sep. 23-24 Register Here Rates by Attend Program Travel Reduced Rates Exhibits + Map Main Program View your save program Award Reception Paticipate Register to Exibit Apply to speak Sp … sed on facilitating the transfer of precision health capabilities into clinical application. Speaker Profile Ph.D., Head of Cellular and Tissue Genomics & Executive Dir, Genentech Orit Rozenblatt-Rosen Biography Orit Rozenblatt-Rosen, PhD, is Head of the Cell and Tissue Genomics (CTG) Department at Genentech. CTG aims to develop and apply high resolution methods to characterize cells and tissues to accelerate scientific discovery and help identify targets and next-gener … for patients. Orit is a pioneer in single-cell genomics technologies and their application to tissues in order to better understand health and disease. Previously, she was the Scientific Director of the Klarman Cell Observatory at the Broad Institute of MIT and Harvard, where she focused on deciphering cellular and tissue circuits. She also co-c
Senior Data Scientist - Multiomic Therapeutics in · Blu Selection Find a Job For Companies Menu Find a Job For Candidates Refer Your Friends Salary Benchmark Study Download Hub For Companies 2026 Barcelona AI Salary Guide Expanding Your Business to Spain (2026) Blog About Blu Contact Us LinkedIn Instagram TikTok Facebook Home Jobs Senior Data Scientist - Multiomic Therapeutics Senior Data Scientist - Multiomic Therapeutics Job details Location Barcelona Job type Senior level - 3 to 5 years Discipline Information Technologies Reference 5765-78 Consultant Gerard Matas SENIOR RECRUITER. View Jobs … hnologies Reference 5765-78 Consultant Gerard Matas SENIOR RECRUITER. View Jobs Apply Now Save this job Back to jobs Senior Data Scientist - Multiomic Therapeutics Job description Location & Work Model : Barcelona or Madrid. A hybrid or remote-first setup so you get the best of both worlds, offering flexibility alongside global team integration. The Project : Multiomic Therapeutics & RNA Drug Discovery. Salary : Between €75,000 and €82,000 gross per year, plus a 12% p … a human, ignore this field Create alert You agree to our Terms & Conditions Apply Now Save this job Share this job linkedin twitter facebook mail whatsapp Similar Jobs Senior Data Scientist - Multiomic Therapeutics Madrid Senior level - 3 to 5 years Senior Data Scientist - Multiomics & AI Disease Reversal Madrid Senior level - 3 to 5 years Senior Data Scientist - Multiomics & AI Disease Reversal Barcelona Senior level - 3 to 5 years [email protected] Tel. +34 932 7
Breakfast Symposium - Toward the full genomic picture: real-time, multiomic profiling in rare disease and pediatric oncology with Oxford Nanopore Sequencing - CCMG | CCGM Skip to content Breakfast Symposium – Toward the full genomic picture: real-time, multiomic profiling in rare disease and pediatric oncology with Oxford Nanopore Sequencing Home » Events » Breakfast Symposium – Toward the full genomic picture: real-time, multiomic profiling in rare disease and pediatric oncology with Oxford Nanopore Sequencing CCMG & Garrod 2026 Joint Conference June 7-10, 2026 Hotel Château-B … ess Password Remember Me Show Password Join Now | Lost Password * Not a member? Apply today . Go to Top
Medical Sponsorship Application Skip to content Products Solutions Learn Company Support Recommended Links Products Instruments Kits & Reagents Selection Tools Software & Analysis Services Popular Products Explore All Products Instruments Sequencing Platforms Microarray Scanners IVD Instruments Financing Options All Instruments NovaSeq X innovation roadmap Future-ready: Built to accelerate performance and value See timeline Kits & Reagents Library Preparation Kits Sequencing Reagents Microarray Kits Clinical Research Products IVD Products All Kits & Reagents Illumina 5-base sol … Large-Scale Bull Genome Sequencing Featured News 2020 Agricultural Greater Good Grant Winner 2019 Agricultural Greater Good Grant Winner Earth BioGenome Project More News Illumina StrataMap Spatial Scalable, unbiased, barrier-free Learn more Methods & Education Complex Disease Genomics Disease Association Studies Gene Target Identification & Pathway Analysis Polygenic Risk Scores Methods Illumina Training Illumina StrataMap Spatial Scalable, unbiased, barrier-free Lea … s Overview Medical Genetics Education Grants & Sponsorships Overview IMPACT Grant Application More Questions Medical Sponsorship Application Medical Sponsorship Application Clinical / Medical Information & Resources / Grants & Sponsorships / Medical Sponsorship Application Contact Information Salutation First Name Last Name Title/Position Phone Number Email Organization Information Legal Entity Name Tax ID Street Address City State State AL (Alabama) AK (Alaska) A … umina Privacy Policy. This step helps prevent unfair use of automated programs. Submit This field is required There was an error submitting your sponsorship. Please try again. Your sponsorship submission has been received. A member from Illumina will be in touch soon with a response. Please do not submit values containing any special characters. Questions or issues? Please reach out to [email protected] . For Research Use Only Not for use in diagnostic procedures … Australian general public. Innovative technologies At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our
Careers. - Multiomic Health home. approach. team. pipeline. news. contact. careers. Search More info Main menu Careers. MULTIOMIC HEALTH OPEN POSITIONS We currently do not have any open positions, but please check back soon. Contact. Want to be a part of our team? Got a partnership in mind? Get in touch with us and know more about how we are changing the face of healthcare. THE COMPANY Multiomic Health Limited is a registered UK company Company #13246608 EMAIL US [email protected] Connect Linkedin Please enable JavaScript in your browser to complete this form. Name * First Last Email … m. Name * First Last Email * Interested in Jobs Partnership Other Message Phone Submit About Multiomic Health Limited is a next-generation precision medicine business, applying computational systems biology to develop and commercialize intellectual property assets for chronic multifactorial diseases Contact info@multiomic.health https://multiomic.health/ PRIVACY NOTICE We take privacy and transparency
Careers. - Multiomic Health home. approach. team. pipeline. news. contact. careers. Search More info Main menu Careers. MULTIOMIC HEALTH OPEN POSITIONS We currently do not have any open positions, but please check back soon. Contact. Want to be a part of our team? Got a partnership in mind? Get in touch with us and know more about how we are changing the face of healthcare. THE COMPANY Multiomic Health Limited is a registered UK company Company #13246608 EMAIL US [email protected] Connect Linkedin Please enable JavaScript in your browser to complete this form. Name * First Last Email … m. Name * First Last Email * Interested in Jobs Partnership Other Message Phone Submit About Multiomic Health Limited is a next-generation precision medicine business, applying computational systems biology to develop and commercialize intellectual property assets for chronic multifactorial diseases Contact info@multiomic.health https://multiomic.health/ PRIVACY NOTICE We take privacy and transpar
Co-Sponsored Chicago Multiomics Mixer | biomodal Skip to content Technology Products Close Products Open Products Products Explore multiple modes of biology from a single sample in a single experiment Discover duet multiomics solution evoC duet multiomics solution +modC Custom solutions modality XPLR Applications Close Applications Open Applications Applications and research areas Multiomic analysis for a greater understanding of normal and disease biology Explore Cancer research Neurodegenerative disease Ageing Precision medicine Liquid biopsy Resources Close Resources Open Resources Resource … using one 5ng DNA sample Read more Attending from biomodal Carmen Guarco Field Application Scientist Jennifer L. Stone, PhD Vice President, Business Development and Customer Solutions Kurt Yardley Director of Global Marketing Mark Consugar Associate Director of Scientific Affairs Thao Huynh Scientific Affairs Partner Register now Meet our team at the event AACR Mixer 29APR25 140331857124 Stay up to date Explore recent biomodal news and the events that we’ll be attendin
Single-Cell Multiomics | Precision Med Tri-Conference About About TRI-CON Attendee Profile & Testimonials Attendees FAQ  Testimonials Archives Agenda Programs Keynotes Brochures Search Agenda Speaker Biographies Networking Sponsor/Exhibitor Prospectus Demographics Become a Sponsor Current Sponsors Exhibit Information Exhibit Services Sponsor & Exhibitor Portal Floorplan Media Media Partners Press Registration Press Resources TRI-CON in the News Diagnostics World News Travel Register Individual Pricing Group Pricing Single-Cell Multiomics Single-Cell Transcriptomics, Genomics, Prot … anscriptomics, proteomics, and imaging data. In this talk, we will showcase its application in studying cancer and neurological disorders, focusing on microenvironments and crosstalk pathways in ovarian cancer, brain and bone metastases, and Alzheimer's disease. 3:05 PM Sponsored by: A Tale of Two Samples: Harnessing the Power of Multiomics from a Single Fresh Sample and a Single FFPE Sample Andrea O’Hara, PhD, Strategic Technical Specialist, Azenta Life Sciences , Str
NextGen Omics, Tech & Data 2026 Explore our brands Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. Events In-Person & Online Events Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities. Biomarkers, CDx & Precision Medicine US 2026 23 - 24 Sep 2026 | San Diego, CA Biomarkers, CDx & Precision Medicine 2026 13 - 14 Oct 202 … ultiplexity is up to 500 markers/ cell. Single cell track keynote address Panel Application Of Single Cell Omics In Clinical Monitoring PRIYA CHOCKALINGAM, Vice President, Head of Clinical BioAnalytics & Translational Sciences, Beam Therapeutics Priya's talk focused on Genome Editing Technologies for Gene & Cell Therapy and how cell & gene therapies require a specialized regulatory approach compared to other modalities. Appropriate assessments should therefore be … o support everything from basic research to translational research and clinical application for immunology, stem cell biology, neuroscience, and cancer. Visit Website Quantum-Si Gold Sponsor Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® Pro benchtop instrument enables Next-Generation Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been po … The NextGen Biomed Young Scientist Awards include the best poster presentation award and are intended to honour an outstanding individual performance for a scientific work by a PhD student, PostDoc or early career scientist. Please submit your poster presentation by no later than 13 th January 2025 in the below category: Protein/Antibody Engineering Bioanalysis & Characterisation Next Generation Biotherapeutics Peptides Chemistry & Therapeutics Oligonucleotides Chemi … th January 2025 ONLY ONE YSA submission per person will be accepted. If authors submit multiple abstracts for consideration for the YSA, only one abstract will be taken into consideration for the YSA Application Instructions Applicants must follow the procedure as follows: Register and submit an abstract by 13 th January 2025 using t
April 29 is coming up fast. GEN's State of Multiomics & NGS Virtual Summit—free, 11:00 AM to 3:00 PM ET—brings together leading voices in spatial biology, NGS, and proteomics. Get a preview of what is in store in the video above. Register here: https://hubs.li/Q04cy50r0 #Multiomics #NGS #StateOfMultiomics Illumina | Genetic Engineering & Biotechnology News
MMC Ventures - Multiomic Health home. approach. team. pipeline. news. contact. careers. Search More info Main menu Backing transformative tech MMC Ventures MMC Ventures is one of the most active early-stage tech investors in Europe. Our investment strategy is focused on enterprise AI, fintech, data-driven health, data infrastructure and cloud. For over two decades, we have partnered with founders from seed and series A stages to help them grow their start-ups. As a research-led investor, we have a deep appreciation for emerging technologies that will reshape our economy over the coming decades
Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photo … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Approach. - Multiomic Health home. approach. team. pipeline. news. contact. careers. Search More info Main menu THE PROBLEM Half the world’s adult population are at risk of cardio-renal-metabolic disease For decades, the term metabolic syndrome described a clustering of abdominal obesity, insulin resistance, dyslipidemia, and hypertension. Today, science recognizes this cluster not as an isolated condition, but as an early expression of a broader, interconnected disease network. Current treatments are imprecise "one-size-fits-all" medicines OUR Approach We seek to transform the lives of patien … m. Name * First Last Email * Interested in Jobs Partnership Other Message Phone Submit About Multiomic Health Limited is a next-generation precision medicine business, applying computational systems biology to develop and commercialize intellectual property assets for chronic multifactorial diseases Contact info@multiomic.health https://multiomic.health/ PRIVACY NOTICE We take privacy and transparency very seriously. To l
Jobs Companies Career Hub CV Analysis Industry Insights Career Guides Roles Library For employers Sign in Find my fit Jobs Companies Career Hub CV Analysis Industry Insights Career Guides Roles Library For employers Sign in Find my fit Multiomic Health Generated by Meeveem AI "AI-enabled precision medicine for cardio-renal-metabolic disease" London • 11 - 50 Employees • Biotechnology Claim this profile for free Connect About About Multiomic Health MultiOmic Health develops precision therapeutics for age-related chronic diseases where genetics alone cannot explain why patients progres
Multiomic Sequencing Methods Skip to content Products Solutions Learn Company Support Recommended Links Products Instruments Kits & Reagents Selection Tools Software & Analysis Services Popular Products Explore All Products Instruments Sequencing Platforms Microarray Scanners IVD Instruments Financing Options All Instruments NovaSeq X innovation roadmap Future-ready: Built to accelerate performance and value See timeline Kits & Reagents Library Preparation Kits Sequencing Reagents Microarray Kits Clinical Research Products IVD Products All Kits & Reagents Illumina 5-base soluti … Large-Scale Bull Genome Sequencing Featured News 2020 Agricultural Greater Good Grant Winner 2019 Agricultural Greater Good Grant Winner Earth BioGenome Project More News Illumina StrataMap Spatial Scalable, unbiased, barrier-free Learn more Methods & Education Complex Disease Genomics Disease Association Studies Gene Target Identification & Pathway Analysis Polygenic Risk Scores Methods Illumina Training Illumina StrataMap Spatial Scalable, unbiased, barrier-free Lea … Australian general public. Innovative technologies At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the
Multiomic Health | MMC Investor Login Investor Login Rectangle About Us Portfolio Team Research & Insights MMC Connect Start Up Jobs Multiomic Health Rectangle AI-enabled precision medicine / Portfolio / Multiomic Health icon-yoi Year of Investment 2023 .01 Investment Status Current .02 Website www.multiomic.health .03 Investment Lead Charlotte Barttelot .04 Next-generation precision medicine Multiomic, a next-generation precision medicine business, is focusing on tackling conditions related to metabolic syndrome. Multiomic is enabling the development of therapeutics through a unique combi … hts Events Podcasts Funds Contact us Never miss out on news and events from MMC Submit x Social Icons/Medium MMC Ventures Ltd is Authorised and Regulated by the Financial Conduct Authority (FCA). Due to legislative requirements, calls may be recorded for monitoring and training purposes. All material unless expressly stated copyright © MMC 2025. Use of this site signifies agreement to the Terms of Use. Due to legislative requirements, calls may be recorded for monitoring and
Multiomic Health Ltd. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 24 Feb 2026 Multiomic Health Ltd. Startups | Holding Company | 2021 | United Kingdom | < 10 | multiomic.health Startups | Holding Company | 2021 | United Kingdom | < 10 | multiomic.health Last update 24 Feb 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Urogenital Diseases Biological products Disease domain score A glimpse into the focused therapeutic areas No Data Technology … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
MultiOmic Health inks MoU with Alloy Therapeutics to discover and develop renal tissue-targeting drugs Home Editorial Services Interview Q&A Chronicle Specials PharMart ePharmail Archives Tenders & Project Tenders & Enquiries Pharma Projects Corporate Company Profiles Corporate Results Corporate X-ray Pharmabiz Studies of Top Companies US FDA UPDATE US FDA: ANDA US FDA: Warnings US FDA: Approved NMEs US FDA: New Approvals EXPORT & IMPORT Drug Export Procedures Drug Units With WHO GMP Certification Pharma Export Data Import Reg. Update PHARMA LAWS &
Mesh Bio and MultiOmic Health partner to use AI to develop precision medicines and diagnostics for chronic metabolic disease Home Solutions Health Screening Result Interpretation Referral HealthVector® Diabetes Articles About Us Book a Demo Home About Us Articles Solutions Health Screening Result Interpretation Referral HealthVector® Diabetes Book a Demo Clinical research on metabolic disease Mesh Bio and MultiOmic Health partner to use AI to develop precision medicines and diagnostics for chronic metabolic disease Singapore-based Mesh Bio , a digital health startup transforming chronic diseas
#leadership #newhire #drugdiscovery #biotech | Multiomic Health | 56 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agr
Michael Sierra - Chief Scientific Officer at Multiomic Health | The Org Platform Enrich Pricing Log in Sign up Multiomic Health Michael Sierra Unverified Michael Sierra Chief Scientific Officer Contact Michael Sierra is an accomplished executive with a PhD in chemistry and extensive experience in drug discovery and technology development. Having led high-performing R&D teams in both large pharmaceutical companies and biotech, Sierra has a proven track record in de-risking disruptive technologies and fostering innovation. Currently serving as the Chief Scientific Officer at Multiomic Heal … isory Board at Proto Axiom and the funding board for the MIT Sandbox Innovation Fund Program. Sierra's educational background includes a Bachelor's degree from Ohio Northern University and advanced studies from Wayne State University and Ecole Polytechnique, complemented by a leadership program at IMD. Location Cambridge, United States Org chart View org chart 1 View manager View position RN Richard Nkulikiyinka Scientific Advisor Rebecca Fairclough Senior Director,
Michael Sierra PhD - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Win Deals Through Your Network Transform relationships with clients, colleagues, and partners into actionable insights. Search for an Executive Trusted by Trusted by Featured Profile Michael Sierra PhD CHIEF SCIENTIFIC OFFICER at MultiOmic Health Michael Sierra PhD 's Executive Work History Current Advisor , Advisor Equilar on 06/10/2026 Proto Axiom CHIEF SCIENTIFIC OFFICER , CHIEF SCIENTIFIC OFFICER Equilar on 06/23/2025 MultiOmic Health Past To view Michael Sierra PhD's complete executive work h
#BIGIMPACT #BIGIMPACT - BIG OPPORTUNITIES Opportunities About Imagine waking up every morning knowing you’re making a difference. When you choose a career in the biotech and life science industry, you’re helping to improve the world around you. From software engineering to data science, the sector is teeming with roles that inspire, challenge and fulfil… Get ready to be one of the game-changers of tomorrow. Do you want to make a #BIGIMPACT? Explore Opportunities LET’S WORK TOGETHER! At BioIndustry Association (BIA), our mission is to drive innovation and be a catalyst for the industry’s growth … urnalist I am a/an: Journalist Machine Learning Scientist Relation Therapeutics Apply now London, UK/ Full-time Andrew Parton Lead Data Scientist MultiOmic Health Read more Ravi Patel Advanced AI Scientist BenevolentAI Read more Aga Dobrowolska Machine Learning Scientist Relation Therapeutics Read more Download Now Get in touch with us for an exclusive interview on the #BIGIMPACT campaign and the biotech industry. Ready to spread the big news? Data Scientist Relation Therapeu … spread the big news? Data Scientist Relation Therapeutics London, UK/ Full-time Apply now DOWNLOAD YOUR INFORMATIOn PACK now!. Learn more about big opportinities that biotech & life sciences field has to offer Get involved 5 / 6 2 / 4 3 / 6 1 / 4 2 / 4 3 / 4 Stop/start motion DOWNLOAD YOUR INFORMATIOn PACK now!. Learn more about big opportinities that biotech & life sciences field has to offer DOWNLOAD YOUR INFORMATIOn PACK now!. Learn more about big opportinities that biotec … egree student Mendelian Read more 1 / 6 Bioinformatician Oxford Nanopore Oxford Apply now Data Analyst (Programmer) Oxford Nanopore Oxford Apply now Solutions Architect Lifebit London Apply now Senior Bioinformatician T-Cypher Bio Oxford Apply now 3 / 4 Alex McVey CEO ogibiotec Read more Nicola Richmond VP of AI BenevolentAI Read more Robyn Liu Biomedical Engineering MEng student ogibiotec Read more Georgiana Neculae Advanced AI Scientist BenevolentAI Read more 6 / 6 Data & C … ientist BenevolentAI Read more 6 / 6 Data & Connectivity Lead AbbVie Marlow, UK Apply now Bioinformatician Laverock Therapeutics Stevenage (Hybrid) Apply now Meet the voices behind #BIGIMPACT choose a career with a feel-good factor. CHOOSE BIOTECH ABOUT The #BIGIMPACT campaign encourages people with digital skills to pursue a career in biotech an
MultiOmic Health and Alloy Therapeutics Collaborate to Discover and Develop Renal Tissue-Targeting Drugs | Ariella Cohain LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join
Ariella Cohain - Chief Technology & Data Officer at Multiomic Health | The Org Platform Enrich Pricing Log in Sign up Multiomic Health Ariella Cohain Unverified Ariella Cohain Chief Technology & Data Officer Contact Deep technical capabilities, strong academic network and author of multiple scientific papers on system biology modeling of cardiometabolic diseases. Most recent prior role was leading a data science team at a Boston-based biotech that was acquired for >$2 billion Location Cambridge, United States Org chart View org chart 1 View manager View position Andrew Parton Asso
MultiOmic Health - Company Profile Solutions Industries Services Resources About Company Directory > Biotech > MultiOmic Health ⚠ Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of MultiOmic Health and believe any information on this page is inaccurate, we will promptly correct or remove it. REPORT AN ERROR MultiOmic Health ↗ London, United Kingdom VISIT WEBSITE MultiOmic Health is an AI-enabled drug discovery (AIDD) company focused on developing precision medicines for chronic, multi-factori
Alasdair Thong - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Win Deals Through Your Network Transform relationships with clients, colleagues, and partners into actionable insights. Search for an Executive Trusted by Trusted by Featured Profile Alasdair Thong CO-FOUNDER & NON-EXECUTIVE DIRECTOR at MultiOmic Health Alasdair Thong 's Executive Work History Current CO-FOUNDER & NON-EXECUTIVE DIRECTOR , CO-FOUNDER & NON-EXECUTIVE DIRECTOR Equilar on 06/23/2025 MultiOmic Health Chief Executive Officer, Sovereign Innovation Division , Chief Executive Offic … ects. He is a co-founder at Multiomic Health and Selvedge Venture (Solo GP seed fund). Prior to joining Alloy he additionally supported BD&L and Acquisitions at the Ellison Institute of Technology, Oxford. Alasdair holds degrees from the University of Cambridge (MPhil) and SOAS, University of London (BA, Hons). Source: Alloy Therapeutics, Inc. on 05/21/2026 Alasdair Thong 's Connections (38) Davide Schiavone Senior Director, Head of Genetically Engineered Organisms and Co … ects. He is a co-founder at Multiomic Health and Selvedge Venture (Solo GP seed fund). Prior to joining Alloy he additionally supported BD&L and Acquisitions at the Ellison Institute of Technology, Oxford. Alasdair holds degrees from the University of Cambridge (MPhil) and SOAS, University of London (BA, Hons). Source: Alloy Therapeutics, Inc. on 05/21/2026 Alasdair Thong 's Connections (38) Davide Schiavone Senior Director, Head of Genetically Engineered Organisms and Co
Alasdair Thong 🎉 The Inclusive Alpha Founder Report is live! Read now Thesis Portfolio Team Research AI Investing Framework Industry Research Inclusive Alpha Founder Report Woman in UK VC Healthy Ageing Research Bio-infrastructure The GLP-1 Economy Impact Report Updates & Insights Sourcing Network Partner with Ada FAQ Talent Network Partner with Ada Partner with Ada FAQ Talent Network Raising Pre-seed? Back to team Alasdair Thong Healthcare Founding Partner at Selvedge Venture Co-Founder and Non-Executive Director at MultiOmic Health Alasdair is a founder in our portfolio and loves using
MultiOmic Health and Alloy Therapeutics Collaborate to Discover and Develop Renal Tissue-Targeting Drugs | Alasdair Thong LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join
MultiOmic Health | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas MultiOmic Health Website: MultiOmic Health Business Area(s) Artificial Intelligence Metabolomics Description Multiomic is a next-generation precision medicine business, applying computational systems biology to develop and commercialize data assets for metabolic syndrome. Career Page(s) career
Press Release - Multiomic Health home. approach. team. pipeline. news. contact. careers. Search More info Main menu Category Archives: Press Release 4 September 2025 Press Release MultiOmic Health and BIO4 Campus Sign MoU to Advance Precision Medicine and Support Bioeconomy Growth in Serbia MultiOmic Health and BIO4 Campus announced the signing of a Memorandum of Understanding (MoU) to explore collaborative opportunities in biomedicine, biotechnology, and bioinformatics, with a strong emphasis on artificial intelligence (AI) applications. Read more BIO4 Collaboration Press Release 2 April 2025
Multiomic Health Careers, Perks + Culture | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Companies Multiomic Health Teams Multiomic Health Save Saved HQ London 18 Total Employees Year Founded: 2021 View Website Overview Jobs Offices Is This Your Company? Claim Profile Artificial Intelligence Healthtech Biotech Multiomic Health is a data-centric therapeutics venture, writing the latest chapter of the precision medicine story by tackling a global, trillion dollar healthcare problem: metabolic syndrome-related con … yond the one-size-fits-all approach currently dominating this disease space. We apply advanced computational systems biology modelling and AI-enabled predictive analytics on deep, standardised patient datasets. These datasets feed into a data lake of thousands of patients, featuring millions of data points per patient accumulated from a wide spectrum of omics, rich clinical phenotyping and various tissue types collected over multiple time points. We use our proprietary MOHSAI
Jobs at Multiomic Health | Hoxton Ventures You are using an outdated browser. Please upgrade your browser to improve your experience and security. CA X LDN About portfolio Team Latest Roles contact Powered by Consider Privacy Terms About portfolio Team Latest Roles contact privacy plan 55 New Oxford Street Eighth Floor London WC1A 1BS United Kingdom
AACR 2026: Subcellular Multiomic Imaging in Cancer Research | Joe Beechem posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you a
MultiOmic Health announces discovery of novel endotypes and biomarkers for diabetic kidney disease - Renal Interventions Facebook Linkedin Mail Twitter Home Latest News Features Profiles Videos Events Supplements Past Issues Subscribe Search Facebook Linkedin Mail Twitter Renal Interventions Home Latest News Features Profiles Videos Events Supplements Past Issues Subscribe Latest News MultiOmic Health announces discovery of novel endotypes and biomarkers for diabetic kidney disease By - 19th November 2024 1316 MultiOmic Health has recently announced the identification of novel patient endotype
Bringing AI algorithms to Medicine: SimplicityBio acquired by Precision for Medicine Get the Kick 1234+ KICKS Portfolio Jury Newsroom About us DONATIONS & LEGACY --> Login Username Password Forgot password / Create a new password EN DE FR Login Get the Kick 1234+ KICKS Portfolio Jury Newsroom About us DONATIONS & LEGACY EN DE FR Get the Kick 1234+ KICKS Portfolio Jury Newsroom About us DONATIONS & LEGACY Login Back to overview Bringing AI algorithms to Medicine: SimplicityBio acquired by Precision for Medicine 06.03.2019 Venture Kick alumni SimplicityBio, provides unlike other AI solutions, th … vely. As artificial intelligence approaches are only as good as the data we can apply them to; joining Precision for Medicine and integrating our AI algorithms into QuartzBioTM multi-omic data integration and informatics platform is a giant leap forward for SimplicityBio and Precision’s clients. We can now provide them with the most robust, sophisticated end-to-end solution for the “big data” challenge observed in biomarker-guided drug development—furthering their mission of
[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [S. 3469 Introduced in Senate (IS)] <DOC> 119th CONGRESS 1st Session S. 3469 To prohibit contracting with certain biotechnology providers. _______________________________________________________________________ IN THE SENATE OF THE UNITED STATES December 11, 2025 Mr. Peters (for himself and Mr. Hagerty) introduced the following bill; which was read twice and referred to the Committee on Homeland Security and Governmental Affairs _______________________________________________________________________ A BILL … er the applicable effective date in subsection (c). (b) Prohibition on Loan and Grant Funds.--The head of an executive agency may not obligate or expend loan or grant funds to, and a loan or grant recipient may not use loan or grant funds to-- (1) procure, obtain, or use any biotechnology equipment or services produced or provided by a biotechnology company of concern; or (2) enter into a contract, or extend or renew a contract, with an entity described in subsection (a)(2). … f concern covered by subsection (f)(2), subsections (a)(2) and (b)(2) shall not apply to biotechnology equipment or services produced or provided under a contract or agreement, including previously negotiated contract options, entered into before the applicable effective date under paragraphs (1) and (2). (B) Safe harbor.--The term ``biotechnology equipment or services produced or provided by a biotechnology company of concern'' shall not be construed to refer to any biotechn … iver. (e) Exceptions.--The prohibitions under subsections (a) and (b) shall not apply to-- (1) any activity subject to the reporting requirements under title V of the National Security Act of 1947 (50 U.S.C. 3091 et seq.) or any authorized intelligence activities of the United States; (2) the acquisition or provision of health care services overseas for-- (A)(i) employees of the United States, including members of the uniformed services (as defined in section 101(a) of title … ithin 90 days after receipt of notice, the biotechnology company of concern may submit information and arguments in opposition to the designation; (iv) describing the procedures governing the review and possible issuance of a designation pursuant to paragraph (1); and (v) where practicable, identifying mitigation steps that could be taken by the
Singular Genomics Unveils G4X™ Spatial Sequencer, Transforming the Landscape of In Situ Multiomic Analysis - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Ce … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Singular Genomics Unveils G4X™ Spatial Sequencer, Transforming the Landscape of In Situ Multiomic Analysis February 5, 2024 | 9 min read Twitter LinkedIn Facebook Email Print Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics t … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BioSkryb Genomics to Present New Single-Cell Multiomic Data at ASHG 2023 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinion … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Bio NC BioSkryb Genomics to Present New Single-Cell Multiomic Data at ASHG 2023 October 30, 2023 | 3 min read Twitter LinkedIn Facebook Email Print BioSkryb Genomics today announced that it will share a wide range of new research related to its recent single-cell multiomic data, single-cell whole genome sequencing and c … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic Offering - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Th … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic Offering October 10, 2023 | 6 min read Twitter LinkedIn Facebook Email Print Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced the expansion of MOx, the … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
biomodal and Element Biosciences Combine Duet Multiomic and High-Throughput Sequencing Capabilities to Advance Clinical Research - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases biomodal and Element Biosciences Combine Duet Multiomic and High-Throughput Sequencing Capabilities to Advance Clinical Research February 23, 2026 | 3 min read Twitter LinkedIn Facebook Email Print CAMBRIDGE, England & SAN DIEGO--(BUSINESS WIRE)--biomodal, an omics-based life sciences technology and a … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
biomodal Delivers the 6-Base Genome with a Powerful New Multiomic Solution, duet evoC - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy C … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search biomodal Delivers the 6-Base Genome with a Powerful New Multiomic Solution, duet evoC February 5, 2024 | 4 min read Twitter LinkedIn Facebook Email Print biomodal, an omics-based life sciences technology and analytics company, today announced it is delivering the 6-base genome to customers with the launch of duet multio … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BioSkryb Genomics to Highlight Power of Next Generation Single-Cell Technology at AGBT 2024 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene The … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Bio NC BioSkryb Genomics to Highlight Power of Next Generation Single-Cell Technology at AGBT 2024 January 30, 2024 | 5 min read Twitter LinkedIn Facebook Email Print BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete DNA-informed multiomic view of the cellular ecosystem, today … orkflow POSTER 534 | Presenter: Jon S. Zawistowski, Ph.D.| Broadening the input application of ResolveDNA genomic amplification to detection of SNV in circulating DNA POSTER 501 | Presenter: Nan Zong (ETH Zurich | Andrew J. deMello Lab) | A droplet-based microfluidic platform combined with primary template-directed amplification (PTA) enables the analysis of clonal heterogeneity and mosaicism in leukemia at single-cell genome level To schedule a demo or meeting at the confere … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform January 7, 2024 | 5 min read Twitter LinkedIn Facebook Email Print Akoya Biosciences, Inc., The Spat … al transcriptomics, single-cell sequencing, or other modalities Development and application of MaxFuse were described in two recent Nature publications MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. , (NASDAQ: AKYA), The Spatial Biology Company®, in collaboration with Enable Medicine, a leading provider of AI-powered biological insights, announces the availability of MaxFuse, an advanced algorithm co-developed in the laboratory of Dr. Garry Nola … s, supporting the acceleration of discoveries and the progress towards clinical application.” A two-part webinar series featuring Garry Nolan and Aaron Mayer entitled "AI-Powered Tissue Atlas: Fusing Single-cell Genomics and Spatial Proteomics with MaxFuse" will be hosted by Genetic Engineering & Biotechnology News (GEN) on February 26th and March 8 th , 2024. * MaxFuse was developed in collaboration with the laboratories of Nancy Zhang and Zongming Ma at the University o … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Metabolon Delivers Large-Scale Metabolomics Dataset to Genomics England's 100,000 Genomes Project to Advance Rare Disease Research - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Metabolon Delivers Large-Scale Metabolomics Dataset to Genomics England’s 100,000 Genomes Project to Advance Rare Disease Research June 24, 2026 | 5 min read Twitter LinkedIn Facebook Email Print Dataset from more than 7,500 participants expands multiomic analysis in rare disease research by combining met … 100,000 Genomes Project, advancing one of the world's most ambitious efforts to apply multiomic methodologies to rare disease research. Metabolon is the first company to generate and deliver a metabolomics dataset of this scale for integration with a large national genomic initiative. Rare diseases affect an estimated 350 million people worldwide and remain among the most challenging conditions to diagnose and treat. More than 7,000 rare diseases have been identified, with ov … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
MultiOmic Health and Alloy Therapeutics Collaborate to Discover and Develop Renal Tissue-Targeting Drugs - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases MultiOmic Health and Alloy Therapeutics Collaborate to Discover and Develop Renal Tissue-Targeting Drugs April 2, 2025 | 4 min read Twitter LinkedIn Facebook Email Print The collaboration provides external validation of MultiOmic Health’s AI-enabled precision medicine discovery platform and innovative ren … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
venturelab - Venture Leaders alumni SimplicityBio is being... Facebook Log In venturelab's Post venturelab March 6, 2019 · Shared with Public Venture Leaders alumni SimplicityBio is being acquired by Precision For Medicine developing QuartzBio™, a multiomic data integration and informatics platform. Unlike other artificial intelligences, SimplicityBio provides the possibility of using multiple biomarkers simultaneously in a white-box design. Read co-founder and CEO Matthew G. Hall 's vision for #AI algorithms in #medicine . http://bit.ly/2TjFRcW All reactions: 3 Like Comment
Multiomic Evaluation of Cell Therapy Distribution Webinar | ACD Easy Editor GUI (script) --> =======[Form]======= --> =======[PreHead]======= --> =======[Head]======= --> =======[Banner]======= --> =======[Hero]======= --> =======[Main]======= --> =======[Aux]======= --> =======[SubFoot]======= --> =======[Foot]======= --> =======[✱ ADMIN]======= --> Contact Us | 1-877-576-3636 Click the HTML icon in the toolbar above to adjust vertical this spacer. TO EDIT: Change the class="spacer-3" to any number between 0 (none) and 5 (most) to resize a spacer. Ex. class="spacer-5" Vertical spacers are res
Member profile: MultiOmic Health | BIA Skip to content Influencing policy Business environment Finance and tax IP and tech transfer Regulation Skills and talent Manufacturing Medicines Access to medicines Cell and gene therapy Antimicrobial Resistance Use of animals in research Critical technologies Biosolutions Engineering Biology TechBio Genomics mRNA Growing the sector Skills, talent and people Sector jobs Resources Future talent Diversity and inclusion Invest in biotech Women in Biotech Developing your company Protecting your company BioStart: for early-stage entrepreneurs Search sector op … our company BioStart: for early-stage entrepreneurs Search sector opportunities Submit a sector opportunity Innovation Map Become a member BIA Membership directory Member benefits Your guide to navigating the BIA website Join BIA member community Save with Business Solutions Join BIA Interested in membership? Enquire about joining BIA News and insights Resources Member news Submit member news Press releases Media centre Sign up to Newscast Blogs Blog guidelines Reports BIA in … lines Reports BIA international Events BIA Events BioSolutions UK Sector events Submit sector events London Life Sciences Week Supporting BIA events Event FAQs About What is biotech? Meet the team Our board Articles of Association Charity partnership Our charity partnerships Careers Our supporters Login/Register Join BIA You are here: BioIndustry Association Member profile: MultiOmic Health MultiOmic Health Drug Discovery Funding stage: Seed Technology type: Tech Bio East Cen
MultiOmic Health and Mesh Bio Partner to Use AI to Develop Precision Medicines and Diagnostics for Chronic Metabolic Disease - Multiomic Health home. approach. team. pipeline. news. contact. careers. Search More info Main menu 30 June 2022 by MultiOmic Health MultiOmic Health and Mesh Bio Partner to Use AI to Develop Precision Medicines and Diagnostics for Chronic Metabolic Disease MultiOmic Health and Mesh Bio Partner to Use AI to Develop Precision Medicines and Diagnostics for Chronic Metabolic Disease 30 June 2022 by MultiOmic Health MultiOmic Health and Mesh Bio announce their partnership
MultiOmic Health partners with BIO4 Campus Belgrade for precision medicine | Multiomic Health posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to jo
History of Illumina Sequencing & Solexa Technology Products Solutions Learn Company Support Recommended Links Products Instruments Kits & Reagents Selection Tools Software & Analysis Services Popular Products Explore All Products Instruments Sequencing Platforms Microarray Scanners IVD Instruments Financing Options All Instruments NovaSeq X innovation roadmap Future-ready: Built to accelerate performance and value See timeline Kits & Reagents Library Preparation Kits Sequencing Reagents Microarray Kits Clinical Research Products IVD Products All Kits & Reagents Illumina 5-b … Large-Scale Bull Genome Sequencing Featured News 2020 Agricultural Greater Good Grant Winner 2019 Agricultural Greater Good Grant Winner Earth BioGenome Project More News Illumina StrataMap Spatial Scalable, unbiased, barrier-free Learn more Methods & Education Complex Disease Genomics Disease Association Studies Gene Target Identification & Pathway Analysis Polygenic Risk Scores Methods Illumina Training Illumina StrataMap Spatial Scalable, unbiased, barrier-free Lea … Australian general public. Innovative technologies At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the
"Interpreting multiomic data: AI and machine learning approaches" | Sapient posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or si
The Pharma Letter Podcast — Episode 15 — Can AI find new drugs for metabolic diseases? - Multiomic Health home. approach. team. pipeline. news. contact. careers. Search More info Main menu 1 July 2022 by MultiOmic Health The Pharma Letter Podcast — Episode 15 — Can AI find new drugs for metabolic diseases? The Pharma Letter Podcast — Episode 15 — Can AI find new drugs for metabolic diseases? 1 July 2022 by MultiOmic Health Click here to listen to the podcast on the Pharma Letter website. The Pharma Letter Podcast — Episode 15 — Can AI find new drugs for metabolic diseases? July 01, 2022 With R
Podcast - Multiomic Health home. approach. team. pipeline. news. contact. careers. Search More info Main menu Category Archives: Podcast 1 July 2022 Interview , Podcast The Pharma Letter Podcast — Episode 15 — Can AI find new drugs for metabolic diseases? In this week’s episode of The Pharma Letter Podcast, MultiOmic chief executive Robert Thong discusses his firm’s progress and ambitions for the future. Read more AI Multiomic Health Podcast Robert Thong The Pharma Letter 1/1 About Multiomic Health Limited is a next-generation precision medicine business, applying computational systems b
Identifying biomarkers of treatment response to ciclosporin in atopic dermatitis through multiomic predictive modelling: DERMATOMICS study protocol | BMJ Open Skip to main content Viewing from: Agence Bibliographique de l Enseignement Superieur (ABES) Intended for healthcare professionals Log In More Log in via Institution Log in via OpenAthens Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * Forgot your log in details? Register a new account? Forgot your user name or password? Log out Basket Search More Search for this k … up for email alerts Thank you to our reviewers Authors Instructions for authors Submit an article Editorial policies Open Access at BMJ Instructions for reviewers BMJ Author Hub Help Contact us Reprints Permissions Advertising Feedback form Accessibility RSS Twitter Facebook Blog Website Terms & Conditions Privacy & Cookies Contact BMJ Cookie Settings Online ISSN: 2044-6055 Print ISSN: 2044-6055 Copyright © 2026 BMJ Publishing Group Ltd. All rights, including for text
Multiomic disease signatures converge to cytotoxic CD8 T cells in primary Sjögren’s syndrome | Annals of the Rheumatic Diseases Skip to main content Intended for healthcare professionals Log In More Log in via Institution Log in via OpenAthens Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * Forgot your log in details? Register a new account? Forgot your user name or password? Basket Search More Search for this keyword Advanced search Archive Search for this keyword Advanced search Close More Main menu Archive Log in More … , Kottyan LC , Weirauch MT . Meta-analysis of differential gene co-expression: application to lupus . Pac Symp Biocomput 2015 : 443 – 54 . ↵ Langfelder P , Luo R , Oldham MC , et al . Is my network module preserved and reproducible? PLoS Comput Biol 2011 ; 7 : 76 8 00 00 . doi:10.1371/journal.pcbi.1001057 OpenUrl ↵ Hänzelmann S , Castelo R , Guinney J . GSVA: gene set variation analysis for microarray and RNA-seq data . BMC Bioinformatics 2013 ; 14 : 7 . doi:10.1186/1471-210
Large-scale multiomic analysis identifies non-coding somatic driver mutations and nominates ZFP36L2 as a driver gene for pancreatic ductal adenocarcinoma | Gut Skip to main content Intended for healthcare professionals Subscribe Log In More Log in via Institution Log in via OpenAthens Log in via BSG Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * Forgot your log in details? Register a new account? Forgot your user name or password? Basket Search More Search for this keyword Advanced search CME/CPD Latest content Current … Leonard 5 , James A Pippin 5 , http://orcid.org/0000-0003-2025-5302 Struan F A Grant 6 , 7 , Tongwu Zhang 8 , Thorkell Andresson 4 , http://orcid.org/0000-0002-1693-5519 Katelyn E Connelly 1 , Jianxin Shi 8 , http://orcid.org/0000-0002-5294-2521 H Efsun Arda 3 , Jason W Hoskins 1 , Laufey T Amundadottir 1 1 Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute , NIH , Bethesda , Maryland , USA 2 The Patrick G Johnston C … il alerts Subscribe Thank you to our reviewers Authors Instructions for authors Submit an article paper Editorial policies Open Access at BMJ BMJ Author Hub Help Contact us Reprints Permissions Advertising Feedback form Accessibility RSS Twitter Facebook Blog Soundcloud YouTube Instagram Linkedin Website Terms & Conditions Privacy & Cookies Contact BMJ Cookie Settings Online ISSN: 1468-3288 Print ISSN: 0017-5749 Copyright © 2026 BMJ Publishing Group Ltd & British
MultiOmic Health forges research collaboration with Northern Care Alliance NHS Foundation Trust in diabetic kidney disease - Multiomic Health home. approach. team. pipeline. news. contact. careers. Search More info Main menu 6 December 2022 by MultiOmic Health MultiOmic Health forges research collaboration with Northern Care Alliance NHS Foundation Trust in diabetic kidney disease MultiOmic Health forges research collaboration with Northern Care Alliance NHS Foundation Trust in diabetic kidney disease 6 December 2022 by MultiOmic Health TUE, 06/12/2022 – 07:30 London, United Kingdom, 6th
Multiomics Market Size, Share, Trends, & Insights Report, 2035 [email protected] | +1 (857) 387 7999 | +44 (748) 188 1310 | Login | --> Register --> | Review Order 0 The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help. --> Home Reports H … grated Omics Platforms, Metabolomics, Proteomics, and Transcriptomics), Type of Application (Cell Biology, Immunology, Neurology, and Oncology), Type of End User (Academic and Research Institutes, Pharmaceutical & Biotechnology Companies, and Others) and Geographical Regions (North America, Europe, Asia, Latin America, and Middle East and North Africa and Rest of the World): Industry Trends and Global Forecast --> Lowest Price Guaranteed Slides 182 Last Updated June 2025 View … mics Integrated Omics Platforms Metabolomics Proteomics Transcriptomics Type of Application Cell Biology Immunology Neurology Oncology Type of End-User Academic and Research Institutes Pharmaceutical & Biotechnology Companies Others Geographical Regions North America US Canada Mexico Other North American countries Europe Austria Belgium Denmark France Germany Ireland Italy Netherlands Norway Russia Spain Sweden Switzerland UK Other European countries Asia China India Japa … his growth due to their versatility and cost reduction. Market Share by Type of Application On the basis of the type of applications, the oncology application is expected to continue to lead the segment (~44%) of the market share till 2035. The ability to analyze tumor heterogeneity at the molecular level by using genomics, proteomics, and metabolomics is advancing the field of oncology. Multiomics enables the identification of tumor biomarkers for early cancer detection and … grated Omics Platforms, Metabolomics, Proteomics, and Transcriptomics), Type of Application (Cell Biology, Immunology, Neurology, and Oncology), Type of End User (Academic and Research Institutes, Pharmaceutical & Biotechnology Companies, and Others) and Geographical Regions (North America, Europe, Asia, Latin America, and Middle East and North A
C4IR Serbia team on a study visit in London and Cambridge - C4IR Serbia About us About C4IR Network Team Partners Projects News Insights Announcements Publications Documents Blog BioTechBEG About the Forum BioTechBEG22 BioTechBEG23 BioTechBEG24 BioTechBEG25 L | E | Ћ About us About C4IR Network Team Partners Projects News Insights Announcements Publications Documents Blog BioTechBEG About the Forum BioTechBEG22 BioTechBEG23 BioTechBEG24 BioTechBEG25 L | E | Ћ NEWS 27.01.2023 C4IR Serbia team on a study visit in London and Cambridge Having in mind the expertise and experience of British experts … e for Molecular genetics and genetic engineering (IMGGE), the Institute for the Application of Nuclear Energy (INEP) and NALED. We were welcomed by the Embassy of Serbia in Great Britain. On that occasion, we met with Ambassador Aleksandra Joksimović and Serbian scientists in London who work for the most prestigious institutions and companies in the mentioned fields, including Oxford. In order to exchange experiences and learn from examples of good practice, we visited Cambri
MultiOmic Health Closes $6.2 Million Funding Round to Discover Precision Medicines for Metabolic Syndrome-Related Conditions - Multiomic Health home. approach. team. pipeline. news. contact. careers. Search More info Main menu 4 May 2023 by MultiOmic Health MultiOmic Health Closes $6.2 Million Funding Round to Discover Precision Medicines for Metabolic Syndrome-Related Conditions MultiOmic Health Closes $6.2 Million Funding Round to Discover Precision Medicines for Metabolic Syndrome-Related Conditions 4 May 2023 by MultiOmic Health View the press release on BusinessWire May 04, 2023 01:00 AM
MultiOmic Health and BIO4 Campus sign MoU to advance precision medicine | BIA Skip to content Influencing policy Business environment Finance and tax IP and tech transfer Regulation Skills and talent Manufacturing Medicines Access to medicines Cell and gene therapy Antimicrobial Resistance Use of animals in research Critical technologies Biosolutions Engineering Biology TechBio Genomics mRNA Growing the sector Skills, talent and people Sector jobs Resources Future talent Diversity and inclusion Invest in biotech Women in Biotech Developing your company Protecting your company BioStart: for ear … our company BioStart: for early-stage entrepreneurs Search sector opportunities Submit a sector opportunity Innovation Map Become a member BIA Membership directory Member benefits Your guide to navigating the BIA website Join BIA member community Save with Business Solutions Join BIA Interested in membership? Enquire about joining BIA News and insights Resources Member news Submit member news Press releases Media centre Sign up to Newscast Blogs Blog guidelines Reports BIA in … lines Reports BIA international Events BIA Events BioSolutions UK Sector events Submit sector events London Life Sciences Week Supporting BIA events Event FAQs About What is biotech? Meet the team Our board Articles of Association Charity partnership Our charity partnerships Careers Our supporters Login/Register Join BIA You are here: BioIndustry Association News and insights Resources MultiOmic Health and BIO4 Campus sign MoU to advance precision medicine Member news 4 Septe
About AbOliGo — Pioneering AOCs for Multiomic Analysis AbOliGo AbOliGo Open main menu Home Products Services Resources Conjugation Chemistry & Methods Bioconjugation Optimization Analytical Characterization Single-Cell & Multi-Omics Protein Interaction Assays Multiplex Panel Design Advanced Imaging & Multiplexing Neuroscience Applications Company About Us News Investors Careers Support Open cart Sign In Sign Up About AbOliGo Pioneering high-performance antibody-oligonucleotide conjugates to unlock the power of multiomic analysis Our Mission "Our mission is to empower scientist
MultiOmic Health | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies MultiOmic Health MultiOmic Health is an AI-enabled drug discovery company dedicated to developing novel therapeutics and diagnostics for serious complications of metabolic dysfunction, which is the world's largest healthcare burden. Using a unique combination of deep longitudinal patient datasets, AI-enabled data science, and experimental biology, they identify patient subpopulations with distinct molecular disease drivers to originate and pursue their ow
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Skip to main content MedPath Trial Home Trials Products Organizations News Research Pricing Search 中 Login Data Sources: ClinicalTrials.gov EU CTR FDA EMA NMPA TGA Health Canada WHO ICTRP MedPath Trial Home Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research. Product Clinical Trials Drug Intelligence Global Approvals AI Research Pricing Resources FAQ Search Company News About Contact Legal Privacy Policy Terms of Service Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medica
Zetta Genomics Acquired by TriNetX, Advancing Precision Medicine | We Venture Capital posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or si … ovided the first catalytic funding through a $10,000 Patriots Pitch Competition award — proving what happens when veterans are given entrepreneurial support, belief, and a platform to execute. Today, in collaboration with HITLAB , IndyGeneUS Bio unveiled a massive blind spot in precision medicine: 88% of genomic data used in drug discovery comes from people of European descent, leaving entire populations underrepresented in the datasets powering AI-driven healthcare and thera … p for being the catalyst making this day possible with a $10,000 Patriots Pitch prize.” Veterans are not just building companies.We are building the future. Crosby Marketing Communications ESPN The Wall Street Journal U.S. Department of Veterans Affairs HillVets Oracle FDA US Army U.S. Army DEVCOM Defense Threat Reduction Agency #Veterans #DAV #PatriotBootCamp #HITLAB #IndyGeneUSBio #PrecisionMedicine #AI #Biotech #BioFinTech #DigitalHealth #VeteranEntrepreneur #HealthcareInn … p for being the catalyst making this day possible with a $10,000 Patriots Pitch prize,” founder Yusuf Nkrumah told DAV. HITLAB The Missing 88%: IndyGeneUS Bio and the Structural Genomic Data Gap in Global Biomedicine | HITLAB hitlab.org 22 5 Comments Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in DAV Patriot Boot Camp 3,697 followers 1mo Edited Report this post A recently released report highlighted the need for IndyGeneUS Bio , a pioneering pla … p for being the catalyst making this day possible with a $10,000 Patriots Pitch prize,” founder Yusuf Nkrumah told DAV. HITLAB The Missing 88%: IndyGeneUS Bio and the Structural Genomic Data Gap in Global Biomedicine | HITLAB hitlab.org 15 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Biosearch Technologies Oligo S
Careers. - Multiomic Health home. approach. team. pipeline. news. contact. careers. Search More info Main menu Careers. MULTIOMIC HEALTH OPEN POSITIONS We currently do not have any open positions, but please check back soon. Contact. Want to be a part of our team? Got a partnership in mind? Get in touch with us and know more about how we are changing the face of healthcare. THE COMPANY Multiomic Health Limited is a registered UK company Company #13246608 EMAIL US [email protected] Connect Linkedin Please enable JavaScript in your browser to complete this form. Name * First Last Email … Name * First Last Email * Interested in Jobs Partnership Other Message Website Submit About Multiomic Health Limited is a next-generation precision medicine business, applying computational systems biology to develop and commercialize intellectual property assets for chronic multifactorial diseases Contact info@multiomic.health https://multiomic.health/ PRIVACY NOTICE We take privacy and transparency
TriNetX Acquires Zetta Genomics Assets To Strengthen Multiomic Data Capabilities 28 June, 2026 | Sunday BioPharma America BioPharma Europe BioPharma Middle East BioPharma Africa BioPharma APAC Events Media Pack Login BioPharma Pharma & Biopharma Manufacturing Pharma Research Pharma QC Clinical Trials Drug Discovery Drug Approval BioSimilar Pharma Packaging LAB LAB Business LAB Health & Safety LAB Products LAB Design LAB Testing Life … g; will continue to support all existing Zetta Genomics customers utilizing the award-winning XetaBase® technology for research and patient care innovation -- TriNetX, the world's leading federated health data network, announced that it has acquired the key assets of Zetta Genomics, a Cambridge, UK-based healthcare technology company and current TriNetX partner. The acquisition expands TriNetX's genomics data management and analytics capabilities, supporting federat
Leveraging AI to Tackle the Looming Metabolic Syndrome Crisis - Multiomic Health home. approach. team. pipeline. news. contact. careers. Search More info Main menu 4 October 2022 by MultiOmic Health Leveraging AI to Tackle the Looming Metabolic Syndrome Crisis Leveraging AI to Tackle the Looming Metabolic Syndrome Crisis 4 October 2022 by MultiOmic Health This article was first published on the Asia-Pacific Biotech News. Click here to view the original article. Leveraging AI to Tackle the Looming Metabolic Syndrome Crisis September & October 2022 by Robert Thong and Andrew Wu Metabolic syn
Precision for Medicine Acquires Industry-leading Artificial Intelligence Technology, Significantly Expands Cloud-based Multiomic Data Integration And Informatics Platform QuartzBio™ Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public … o adds: "Artificial intelligence approaches are only as good as the data we can apply them to; joining Precision for Medicine and integrating our AI algorithms into QuartzBio is a giant leap forward for our customers and industry, as multiomic data grows in quantity and complexity." About Precision for Medicine Precision for Medicine is the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeti … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
MultiOmic Health announces discovery of novel endotypes and biomarkers for diabetic kidney disease - Multiomic Health home. approach. team. pipeline. news. contact. careers. Search More info Main menu 12 November 2024 by MultiOmic Health MultiOmic Health announces discovery of novel endotypes and biomarkers for diabetic kidney disease MultiOmic Health announces discovery of novel endotypes and biomarkers for diabetic kidney disease 12 November 2024 by MultiOmic Health read the press release on Sciad Newswire London, UK, 12 th November 2024 / MultiOmic Health , a leading AI-enabled drug discove
News. - Multiomic Health home. approach. team. pipeline. news. contact. careers. Search More info Main menu News. 4 September 2025 Press Release MultiOmic Health and BIO4 Campus Sign MoU to Advance Precision Medicine and Support Bioeconomy Growth in Serbia MultiOmic Health and BIO4 Campus announced the signing of a Memorandum of Understanding (MoU) to explore collaborative opportunities in biomedicine, biotechnology, and bioinformatics, with a strong emphasis on artificial intelligence (AI) applications. Read more BIO4 Collaboration Press Release 2 April 2025 Press Release MultiOmic Health and
Precision for Medicine Acquires Industry-leading Artificial Intelligence Technology, Significantly Expands Cloud-based Multiomic Data Integration and Informatics Platform QuartzBio™ - Precision Medicine Group Skip to content about story leadership board of directors ethics & compliance sustainability principles services insights careers contacts story board of directors ethics & compliance sustainability principles services insights careers contacts Previous Next Precision for Medicine Acquires Industry-leading Artificial Intelligence Technology, Significantly Expands Cloud-based Mul … o adds: “Artificial intelligence approaches are only as good as the data we can apply them to; joining Precision for Medicine and integrating our AI algorithms into QuartzBio is a giant leap forward for our customers and industry, as multiomic data grows in quantity and complexity.” About Precision for Medicine Precision for Medicine is the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeti
Pipeline. - Multiomic Health home. approach. team. pipeline. news. contact. careers. Search More info Main menu pipeline. MULTIOMIC HEALTH PIPELINE Active program pipeline advancing towards preclinical candidates all programs target dysfunctional pathways implicated in kidney inflammation and fibrosis (multiple aetiologies) Contact. Want to be a part of our team? Got a partnership in mind? Get in touch with us and know more about how we are changing the face of healthcare. THE COMPANY Multiomic Health Limited is a registered UK company Company #13246608 EMAIL US [email protected] Connect L … rm. Name * First Last Email * Interested in Jobs Partnership Other Message Name Submit About Multiomic Health Limited is a next-generation precision medicine business, applying computational systems biology to develop and commercialize intellectual property assets for chronic multifactorial diseases Contact info@multiomic.health https://multiomic.health/ PRIVACY NOTICE We take privacy and transparency very seriously. To l
MultiOmic Health and Alloy Therapeutics Collaborate to Discover and Develop Renal Tissue-Targeting Drugs - Multiomic Health home. approach. team. pipeline. news. contact. careers. Search More info Main menu 2 April 2025 by MultiOmic Health MultiOmic Health and Alloy Therapeutics Collaborate to Discover and Develop Renal Tissue-Targeting Drugs MultiOmic Health and Alloy Therapeutics Collaborate to Discover and Develop Renal Tissue-Targeting Drugs 2 April 2025 by MultiOmic Health The collaboration provides external validation of MultiOmic Health’s AI-enabled precision medicine discovery platform
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Multiomic Health - AI-Enabled Precision Medicine for Metabolic Syndrome home. approach. team. pipeline. news. contact. careers. Search More info Main menu Multiomic Health AI-enabled precision medicine for cardio-renal-metabolic disease find out more. ABOUT. MultiOmic Health has built a platform for discovering and developing life-changing precision medicines for age-related chronic multifactorial diseases where genetics alone cannot explain why numerous patients continue to progress despite being treated on standard of care. Our initial focus is the cardio-renal-metabolic landscape, a group o … m. Name * First Last Email * Interested in Jobs Partnership Other Message Phone Submit About Multiomic Health Limited is a next-generation precision medicine business, applying computational systems biology to develop and commercialize intellectual property assets for chronic multifactorial diseases Contact info@multiomic.health https://multiomic.health/ PRIVACY NOTICE We take privacy and transparency very seriously. To l
Collaboration with Alloy to develop renal drugs | Multiomic Health posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to … -Pro supports the rational design of more selective and safer therapeutics. Its application in drug screening demonstrates significant potential to accelerate early-stage drug discovery and optimize compound selection, marking a notable advancement in the development of next-generation covalent medicines. A new analytical tool can optimize the potency and selectivity of drugs phys.org 2 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Peter Siman
Illumina, Inc. - Illumina transforms multiomic research with new technologies to unlock deeper understanding of biology Skip to main content Skip to main content Go to illumina.com Press Release Investors Overview Events & Presentations Stock Information Stock Quote Stock Chart Historical Stock Quote Investment Calculator Analyst Coverage Financials Quarterly Results SEC Filings ESG GRAIL Acquisition Governance Resources Investor FAQs Investor Email Alerts Investor Contacts View All News Illumina transforms multiomic research with new technologies to unlock deeper understanding of biology Febr … Q1’21 Earnings Results --> Innovative technologies At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the
Team. - Multiomic Health home. approach. team. pipeline. news. contact. careers. Search More info Main menu TEAM. OPERATING TEAM Linkedin Ro bert Tho ng Co-founder & CEO 30+ years in biopharma & healthcare, focusing on R&D management , B2B partnerships and value creation strategy . Has engaged with over 100 organizations in biopharma, medical technology and healthcare. Published authority on biopharma R&D partnerships and biotech business models Linkedin Ce lia Sch ell CHIEF CLINICAL OFFICER & CHIEF OPERATING OFFICER 14 years experience in clinical research at Novartis and … from academia Linkedin Valeryia Kuzmuk ASSOCIATE DIRECTOR TRANSLATIONAL SCIENCE Award-winning renal biologist . Has taken a novel therapeutic from unvalidated target to development candidate for Phase I. Previously at a UK biotech managing drug discovery assays and preclinical development studies Linkedin Es ra Ber kol CHIEF OF STAFF Broad experience base of international collaborative activities . Product manager in a B2B financial data & solutions provider. Project mana … rm. Name * First Last Email * Interested in Jobs Partnership Other Message Name Submit About Multiomic Health Limited is a next-generation precision medicine business, applying computational systems biology to develop and commercialize intellectual property assets for chronic multifactorial diseases Contact info@multiomic.health https://multiomic.health/ PRIVACY NOTICE We take privacy and transparency very seriously. To l
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.